Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. - Wikidata - awgldk - TriplyDB

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.

http://www.wikidata.org/entity/Q34476161

about

Beta-thalassemia Oral deferiprone for iron chelation in people with thalassaemia Oral deferiprone for iron chelation in people with thalassaemia Impact of cardiac magnetic resonance imaging in non-ischemic cardiomyopathies Guidelines on haemovigilance of post-transfusional iron overload MRI Measurements of Iron Load in Transfusion-Dependent Patients: Implementation, Challenges, and Pitfalls The emerging clinical role of cardiovascular magnetic resonance imaging.Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.Evidence for a novel mechanism independent of myocardial iron in β-thalassemia cardiac pathogenesis.Safety and efficacy of iron chelation therapy with deferiprone in patients with transfusion-dependent thalassemia.Assessment of cardiac iron by MRI susceptometry and R2* in patients with thalassemia Liver iron content determination by magnetic resonance imaging.Complications and treatment of patients with β-thalassemia in France: results of the National Registry.Cardiac iron across different transfusion-dependent diseases.International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers.Advances in iron chelation: an update.Design of iron chelators with therapeutic application.Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek Unit.How I treat Diamond-Blackfan anemia.Cardiovascular magnetic resonance T2* for tissue iron assessment in the heart.Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance Value of black blood T2* cardiovascular magnetic resonance.Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload.On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure.Iron-induced damage in cardiomyopathy: oxidative-dependent and independent mechanisms.Agranulocytosis due to deferiprone: a case report with cytomorphological and functional bone marrow examination Efficacy and safety of Iranian made Deferasirox (Osveral®) in Iranian major thalassemic patients with transfusional iron overload: A one year prospective multicentric open-label non-comparative study.Treatment of β-Thalassemia/Hemoglobin E with Antioxidant Cocktails Results in Decreased Oxidative Stress, Increased Hemoglobin Concentration, and Improvement of the Hypercoagulable State Management of transfusional iron overload - differential properties and efficacy of iron chelating agents.Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major.Estimating tissue iron burden: current status and future prospects.Impaired iron status in aging research Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET.Exjade(R) (deferasirox, ICL670) in the treatment of chronic iron overload associated with blood transfusion.Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats T1 at 1.5T and 3T compared with conventional T2* at 1.5T for cardiac siderosis.

P2860

Q21202886-6E9D889F-CABD-4563-B49F-4FC5075039FD Q24200309-2EEF2ADA-DF99-4ED9-9FDA-8BF9309A4E54 Q24244045-A6557AD4-C77F-49FF-80B9-EF65064688AF Q26765173-ED862BBC-37A5-440C-9A87-2FEDA83E18B5 Q27022721-A5D796B7-809C-43E0-9605-DB2ADEE57486 Q28072173-F365A8A1-EBF0-40B6-B8DA-9AB355A24A9F Q30475257-505E0EAE-5632-4F55-9FED-27B73237399A Q31037298-2843C190-1C17-418C-8B0B-0F9881100062 Q31110125-19DFF8BD-A80D-4F85-835A-38EC2B0D6031 Q33407282-D6B1EA43-08A4-4D72-8C08-421849AA8F0E Q33729649-A79D4BB2-E60D-4716-82A7-8AC721B94F89 Q33764777-FA95186C-C743-4B49-A5DF-EC9C69B7F4EB Q33829058-89B212C0-D722-4D63-84A1-2EFE64D6121E Q33958560-39991BC7-7F75-44DC-80C4-BFC8E2CCFA63 Q34158260-260D1284-74C6-48D0-87B5-5334D6332EAB Q34174307-4CB0D88E-128E-44C2-A75C-6601AAB11199 Q34258805-790DF5D9-A503-4CA7-A0D8-BFC29C3F0326 Q34269245-573C38C5-CD78-4C01-8DC5-A17A99B5A0A2 Q34310852-3030C18E-345F-4360-AB98-05365AA26088 Q34422736-E30BAFDC-C08C-42B1-A818-E4D616D2FA4C Q34451519-044DEBDA-19F6-45BC-8844-C3B686F66FDC Q34451527-41844A6B-4372-4BB4-8C4E-6BC9BE278C2A Q34515540-3359B0E3-0EAC-4B95-BF32-CCB7ED775644 Q34706719-9C76AADE-01C7-410B-A2F3-562BFA382207 Q35077670-CDCC21D4-9B02-4962-9F40-0D08520A4BDD Q35143774-3B81808F-B1A0-4784-B3A0-1160CB1EC379 Q35232747-B10A9BB0-3646-4DFE-A3DB-07C2A671A4F4 Q35296244-59BE159F-E423-4824-8EF4-971CBFDBD1F7 Q35434460-AEEEC9E7-4F7B-427B-8440-8561B877BB5F Q35596533-A6D99AA6-6AFC-4415-B685-C3767721AE5B Q35675094-F706E542-4E3A-4566-8B73-77E1C765157B Q35683841-F7261D64-CC81-430A-B813-A2A4B3DD7815 Q35753526-83542B24-0ECD-4D1C-AB9E-0FA875AF0BF6 Q35793545-BD5DDA65-2BE0-4CF8-9D3C-DE15CB1A66BA Q35795910-11DC7CFA-ECB7-4E81-A566-110C6297C40D Q35813192-5F3D5327-192A-4F3F-8926-63451345F752 Q35906193-B5DDF252-16D3-4AD7-B966-915757101F9B Q35919222-7BAE0B40-570A-49AD-809E-C3AE28649542 Q36080315-96CFD9FB-57B9-46B9-870E-42AC65CA9A49 Q36318293-4CC3005E-AE8D-4DFA-A1D5-1780E4F16F27

P2860

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis.

http://www.wikidata.org/entity/Q34476161

description

2005 nî lūn-bûn

@nan

2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Randomized controlled trial of ...... ptomatic myocardial siderosis.

@ast

Randomized controlled trial of ...... ptomatic myocardial siderosis.

@en

Randomized controlled trial of ...... ptomatic myocardial siderosis.

@nl

type

label

Randomized controlled trial of ...... ptomatic myocardial siderosis.

@ast

Randomized controlled trial of ...... ptomatic myocardial siderosis.

@en

Randomized controlled trial of ...... ptomatic myocardial siderosis.

@nl

prefLabel

Randomized controlled trial of ...... ptomatic myocardial siderosis.

@ast

Randomized controlled trial of ...... ptomatic myocardial siderosis.

@en

Randomized controlled trial of ...... ptomatic myocardial siderosis.

@nl

P1433

Q34476161-E52CBD30-1F00-4875-8019-5F15613A97E2

P1476

Q34476161-6BD7FDAC-EA39-4C0C-955B-D58779E37D68

P2093

Q34476161-0FC4D5F1-8672-43BB-AF41-05C423C8AC32

Q34476161-5C30575C-2364-4F1A-B1B3-BF3FA611E42D

Q34476161-606E7BEB-3A1B-47D5-8E6D-C5B22C61668A

Q34476161-6D0AE036-89C3-47A8-8F1E-7C0F3D2EC464

Q34476161-8B104603-710C-486C-89A2-1985D23AFCD1

Q34476161-92EBD842-D6FC-4BCC-A20E-D1B1E18B8BAE

Q34476161-9B9E3CD3-3FB1-4706-970B-83ECD66CC9F0

Q34476161-9E572889-2F5D-49E2-B69D-7DB04C7D739B

Q34476161-A4A07C53-D33A-427D-911D-932149F3A628

Q34476161-E9B7913F-60C1-4787-8EDA-BC9EE87C0FE5

P304

Q34476161-2FECE1EC-2A60-42F4-974C-1BDC2C675985

P31

Q34476161-E833F7FC-3A1B-400D-9821-83A370FE1000

P356

Q34476161-61DE8A4B-42DB-40A4-B949-4E8D23F6C1BA

P407

Q34476161-009EDAAD-815B-4CD0-A918-C8A03067C3BA

P433

Q34476161-82C0401E-37C8-44D3-A3C7-EE8F5ECC41D0

P478

Q34476161-7503E227-D7AB-4F58-A247-45254226BDF4

P50

Q34476161-D977CAF5-509E-4442-A127-B5626C6AA04A

P577

Q34476161-347DDEDB-BBF2-4A62-B69B-9D618F4501B2

P5875

Q34476161-87AEEE9A-8F8E-4D8E-A65A-22D9411F8ACB

P698

Q34476161-59063737-EA7A-4023-A587-392C742FB2A6

P921

Q34476161-D8C347ED-B433-4BF4-9A6E-BD4969D4966F

P356

BLOOD-2005-07-2948

P1433

P1476

Randomized controlled trial of ...... ptomatic myocardial siderosis.

@en

P2093

Antonio Piga

http://www.w3.org/2001/XMLSchema#string

Athanassios Aessopos

http://www.w3.org/2001/XMLSchema#string

Beatrix Wonke

http://www.w3.org/2001/XMLSchema#string

Efstathios D Gotsis

http://www.w3.org/2001/XMLSchema#string

Gill C Smith

http://www.w3.org/2001/XMLSchema#string

Mark A Tanner

http://www.w3.org/2001/XMLSchema#string

Mark A Westwood

http://www.w3.org/2001/XMLSchema#string

Markissia Karagiorga

http://www.w3.org/2001/XMLSchema#string

Renzo Galanello

http://www.w3.org/2001/XMLSchema#string

Vasili Berdoukas

http://www.w3.org/2001/XMLSchema#string

P304

3738-3744

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-07-2948

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7416846

http://www.w3.org/2001/XMLSchema#string

P698

16352815

http://www.w3.org/2001/XMLSchema#string

P921